Meta Pixel

News and Announcements

Trustee Tailored Super Update

  • Published June 26, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Trustee Tailored Super (TTS) provides Australia’s 100 largest superannuation trustees an IP protected better solution compared to the current default option choices (being a one-size-fits-all ‘Balanced’ investment option or age-only based ‘Life-Stage’). It covers the majority, 75+%, of members who have not advised their trustee of an investment option for their collective $550 billion super balances.

ESIC status may provide investors ten years CGT free and 20% tax back – just in time for EOFY planning.

We are pleased to confirm that on 26 May 2017 we received confirmation of Early Stage Investor Company (ESIC) status from the ATO.

In May 2017, it was confirmed by Super Ratings, that 32 funds are failing the APRA Member Assessment (Scale) Test, leading to a call for the regulator to merge them. Further the bulk of funds, 68%, were behind requirements and for those MySuper funds in this precarious position it could “spell their death knell”.

Tailoring to members’ retirement prospects using TTS can be the solution for these funds! It beats the APRA test, is a member attraction strategy and outstrips, up to tenfold, the alternative (0.10% to 0.15%) merger scale benefits.

Time to replace that bucket
We continue to highlight, that without Smart Defaults like TTS, in 2050 it’s projected that 80% will still need support through the Age Pension, plus that 4.5 workers now fund that per pensioner – 2.7 workers will need to. It’s getting worse and we know what happened to Japan as the population aged! This global issue was highlighted in a May 2017 report by the World Economic Forum.

Super is good but it’s not yet achieving its retirement objective. However with innovation and TTS it could by tailoring MySuper investment options. Creates a third increase, $5 billion per year – not insignificant to the current $44+ billion Age Pension cost or the 2050 estimated shortfall of $136 billion.
At the national level, the Financial Services Council is producing a report on TTS and in July 2017 we are presenting at their Leaders Summit. We have also briefed Federal Treasury and are hopeful they will run a version of TTS in their new MARIA model on the whole 14.5 million MySuper accounts.

Funds are racing each other to shore-up MySuper member attraction programs. None want to be paying out more in pension dollars than they receive in contributions to invest!

As industry stalwart, Jeremy Cooper pointed out in May, “it’s at the customer interface where industry is vulnerable…just imagine, if a Google/big global tech company turned up with an interface for super and some kind of global investment concept, the industry here would not be able to compete… super funds have Apps but they’re pretty lame…If someone did it right, something with real value and not just a gimmick, there would be a stampede effect out of the existing funds”.
Well it’s here, don’t need a Google or global – just one trustee willing to Act on TTS by taking 1st adopter risk on an Australian invention – watch this space!

Please click the link on the right hand side for more information.

Request Offer

Capital Insights
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.

Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation

Capital Insights
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula

Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.

Join over 45,000+ sophisticated investors

Join Now